Chehrehgosha, Haleh Sohrabi, Masoud Reza Ismail-Beigi, Faramarz Malek, Mojtaba Reza Babaei, Mohammad Zamani, Farhad Ajdarkosh, Hossein Khoonsari, Mahmood Fallah, Afshin Eshghi Khamseh, Mohammad E.
...
Published in
Diabetes Therapy
Introduction To evaluate the efficacy of empagliflozin compared to pioglitazone in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM). Methods In this prospective randomized, double-blind, placebo-controlled trial, we assigned 106 patients with NAFLD and T2DM to receive empagliflozin 10 mg ( n = 35), pioglitazone 30 ...
Williams, David M. Ruslan, Aliya M. Khan, Rahim Vijayasingam, Daneeshanan Iqbal, Fizzah Shaikh, Ayesha Lim, Jia Chudleigh, Richard Peter, Rajesh Udiawar, Maneesh
...
Published in
Diabetes Therapy
Introduction The glucagon-like peptide-1 receptor analogue (GLP-1RA) semaglutide is associated with improvements in glycaemia and cardiovascular risk factors in clinical trials. The aim of this study was to examine the real-world impact of semaglutide administered by injection in people with type 2 diabetes (T2D) across three secondary care sites i...
Aberer, Felix Hochfellner, Daniel A. Mader, Julia K.
Published in
Diabetes Therapy
The utilization of telemedicine solutions to reduce outpatient clinic visits and visits to physicians' offices, thus saving financial and personal resources as well as time, has gained substantial importance in recent years. The COVID19 pandemic has made it necessary to abruptly adjust outpatient care methods in various medical settings that needle...
Ishii, Hitoshi Hansen, Brian B. Langer, Jakob Horio, Hiroshi
Published in
Diabetes Therapy
Introduction In the randomized Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) 10 trial, once-daily orally administered semaglutide—the first oral glucagon-like peptide 1 receptor agonist (GLP-1RA)—was similarly tolerated with comparable (at 7 mg) or better (at 14 mg) efficacy versus the injectable GLP-1RA dulaglutide 0.75 mg. Health-rela...
Ishii, Hitoshi Nakajima, Hiroki Kamei, Nozomu Uchida, Daigaku Suzuki, Daisuke Ono, Yasuhiro Sato, Yasunori Shimono, Dai
Published in
Diabetes Therapy
Introduction In Japan, patient-led insulin titration is rare in type 2 diabetes mellitus (T2DM) patients. Few studies have compared the effects of patient-led versus physician-led insulin titration on patient-reported outcomes in Japanese T2DM patients. This study aimed to compare the effects of patient-led and physician-led insulin titration in Ja...
Rattelman, Cori R. Ciemins, Elizabeth L. Stempniewicz, Nikita Mocarski, Michelle Ganguly, Rahul Cuddeback, John K.
Published in
Diabetes Therapy
People with type 2 diabetes have their glycated hemoglobin (HbA1c) level measured regularly by their care provider to check their blood sugar levels over the previous 2–3 months and the diabetes control achieved with their current treatment. To keep HbA1c within an individually recommended range, changes to therapies or doses may be needed, which i...
Chen, Xiaoyu Su, Haihua Kunii, Daisuke Kudou, Kousuke Zhang, Yiyan Zhao, Ying Zhang, Dan Xing, Yuanyuan Teng, Jiaqi Nie, Zhiqiang
...
Published in
Diabetes Therapy
Bue-Valleskey, Juliana Klaff, Leslie Cho, Jang Ik Dellva, Mary Anne Schloot, Nanette C. Tobian, Janet Miura, Junnosuke Dahl, Dominik
Published in
Diabetes Therapy
Introduction The PRONTO-T1D study, which evaluated the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes (T1D), met the primary endpoint of noninferiority of HbA1c change from baseline compared to lispro at 26 weeks. We present results of an additional 26-week treatment phase evaluating long-term efficacy...
Shah, Viral N. Franek, Edward Wernicke-Panten, Karin Pierre, Suzanne Mukherjee, Bhaswati Sadeharju, Karita
Published in
Diabetes Therapy
Introduction The biosimilar SAR341402 insulin aspart (SAR-Asp) was compared to its originator NovoLog®/NovoRapid® insulin aspart (NN-Asp) in terms of efficacy, safety, and immunogenicity, in adults with type 1 or type 2 diabetes switching from different rapid-acting insulin analogs. Methods This phase 3, randomized, open-label, multinational, 52-we...
Capehorn, Matthew Hallén, Nino Baker-Knight, James Glah, Divina Hunt, Barnaby
Published in
Diabetes Therapy
Introduction Type 2 diabetes represents a continuing healthcare challenge, and choosing cost-effective treatments is crucial to ensure that healthcare resources are used efficiently. The present analysis assessed the cost-effectiveness of once-weekly semaglutide 1 mg versus empagliflozin 25 mg for the treatment of patients with type 2 diabetes mell...
